Specimen Analyses

 

Study & PI
Summary
SARS-CoV-2 Surveillance for Infected Individuals or High Risk Subjects and Antibody Reverse Engineering

PI: David Graham
The ultimate goal of this study is to determine if reverse engineered antibodies against the Spike (S) protein of SARS-CoV-2 can be developed as both a therapy and prophylaxis for COVID-19. IRB approval of this protocol is currently limited to a Phase I pilot, feasibility study carried out on post-infection, convalescent healthcare workers, to define the population from whom the peripheral blood mononuclear cells (PBMC) are to be isolated for this process.
SARS- CoV-2 in Human Tissues

PI: David Nauen
In collaboration with the Howard Hughes Medical Institute, de-identified postmortem samples from patients with COVID-19 as well as potentially uninfected individuals, will be used to study infection by SARS-CoV-2 and tissue responses. Primary means of investigation include light and electron microscopy, as well as studies of RNA and protein. Tissues of interest include heart, lung, and brain.
Ashewell COVID-19 Study

PI: Robert Yolken
Antibodies specific for COVID-19 proteins will be measured in blood samples obtained as part of an ongoing study to determine the relationship between exposure to COVID-19 and the physical and mental health of patients in a group medical practice located in Asheville, North Carolina.
Isolation of Potent Neutralizing Human Monoclonal Antibodies against SARS-CoV-2

PI: Justin Bailey

The primary goal of this study is to isolate monoclonal antibodies (mAbs) from infected individuals which target the SARS-CoV-2 S protein receptor binding domain and which could have potential as therapeutic or prophylactic agents for COVID-19 disease. A secondary goal is to compare the mAbs isolated from individuals who have recovered from milder disease versus those obtained from patients with moderate to severe disease, to better understand the role of anti-SARS-CoV-2 antibodies in the immunopathogenesis of COVID-19 disease.